Depressive

Neuroelectrics Announces Results of Telemedicine Pilot Depression Study with Starstim tDCS Therapy

Retrieved on: 
Thursday, March 7, 2024
Science, Biotechnology, Telemedicine, Virtual Medicine, Research, Health, Mental Health, Medical Devices, Clinical Trials, Electrode, Depressive, Multimedia, Preprint, Satisfaction, Grammatical mood, Quick, Deep brain stimulation, Safety, Quality of life, Patient, DSM-IV codes, Harvard Medical School, MDD, Brain, Depression, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20240307614300/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240307614300/en/
    The preprint, titled “Multichannel tDCS with Advanced Targeting for Major Depressive Disorder: A Tele-Supervised At-Home Pilot Study,” highlights results from a multicenter, open-label feasibility telemedicine pilot study that studied the efficacy, safety, and feasibility of home-based tDCS using Starstim to target the L-DLPFC.
  • The study was conducted across multiple centers and involved 35 participants diagnosed with medication-resistant MDD to evaluate tDCS administered at home using Neuroelectrics’ Starstim device.
  • Results from this study highlight the safety and feasibility of at-home tDCS, with nearly 90% of participants completing the treatment without experiencing any adverse effects.
  • “We’re excited to announce the results of our telemedicine pilot study, showcasing the transformative potential of at-home tDCS therapy with our Starstim device in managing MDD,” said Ana Maiques, CEO & Co-Founder, Neuroelectrics.

QHSLab, Inc. Meets the Demand for Updated Mental Health Screening Recommendations from the U.S. Preventive Services Task Force

Retrieved on: 
Tuesday, November 1, 2022
Security (finance), Algorithm, Vital signs, Depressive, WEST, Relaxation, Budget, Sleep, Pain, U.S. Securities and Exchange Commission, Health, The Quality of Life Assessment of Growth Hormone Deficiency in Adults Measure, Assessment, OTCQB, Efficiency, Patient Health Questionnaire, Exercise, GLOBE, Patient, Risk, Physician, GAD, Anxiety disorder, USPSTF, Anxiety, Education, Digital, Private Securities Litigation Reform Act, PCP, Company, PALM, United, Pediatrics, Medicare, United States Public Health Service, United States Preventive Services Task Force, Ageing, Primary care, Quality of life, Forward-looking statement, PHQ, Digital health, Depression, ALL, Health insurance, Medical device, Medicine, Risk management, Medicaid

WEST PALM BEACH, FL, Nov. 01, 2022 (GLOBE NEWSWIRE) -- QHSLab, Inc. (the “Company”) (OTCQB: USAQ), a company focused on providing clinicians with tools to leverage proactive, value-based healthcare solutions through emerging digital health and point-of-care technologies, validates the growing need for the Q-Scale, or “Quality of Life” Scale, a digital medicine assessment tool for screening patients who may be suffering from mental and emotional health-related issues. A recent report from the U.S. Preventive Services Task Force (USPSTF) recommended that ALL patients under the age of 65, including children and adolescents aged 8 to 18 years, be screened for depression and anxiety in their primary care appointments. USPSTF made some of the following comments: 

Key Points: 
  • The independent, non-partisan group, U.S. Preventive Services Task Force, recommends screenings for depression and anxiety among all patients under the age of 65.
  • Primary Care Physicians and pediatricians are often under-equipped to meet the growing demand for mental health services, and need screening tools to ensure efficiency and proper diagnosis.
  • QHSLab, Inc. provides primary care physicians (PCPs) and pediatricians with the digital tools to meet these proposed national mental health guidelines.
  • They are often the first resource seen by patients presenting a mental health concern and can uncover an undiagnosed mental health condition.

Alex Therapeutics presents results from digital therapeutic pilot study showing nearly 50% reduction in anxiety

Retrieved on: 
Thursday, October 13, 2022
LinkedIn, Single-frequency network, CBT, Pulmonary fibrosis, Therapy, Population, Depressive, IPF, Pfizer, PF, Patient, Digital therapeutics, GAD-7, Partnership, Trial of the century, Idiopathic pulmonary fibrosis, CEO, Degenerative disease, Safety, Aircraft pilot, Clinical trial, Anxiety, Digital, SAMD, Fine chemical, Pharmaceutical industry, Medical device, Vicor Corporation

Today they announce positive results from the pilot phase of a clinical study[2]for one of their digital therapies treating anxiety in patients with the rare disease IPF.

Key Points: 
  • Today they announce positive results from the pilot phase of a clinical study[2]for one of their digital therapies treating anxiety in patients with the rare disease IPF.
  • The Pilot study was a 4-week, single-arm, decentralized, open-label clinical investigation in 10 patients with self-reported anxiety related to idiopathic pulmonary fibrosis (IPF).
  • "We're very pleased with these early efficacy results for one of our anxiety Digital Therapeutics'.
  • Alex Therapeutics is a digital therapeutics (DTx) company that partners with pharmaceutical companies to create and license digital therapies.

Alex Therapeutics presents results from digital therapeutic pilot study showing nearly 50% reduction in anxiety

Retrieved on: 
Thursday, October 13, 2022
LinkedIn, Single-frequency network, CBT, Pulmonary fibrosis, Therapy, Population, Depressive, IPF, Pfizer, PF, Patient, Digital therapeutics, GAD-7, Partnership, Trial of the century, Idiopathic pulmonary fibrosis, CEO, Degenerative disease, Safety, Aircraft pilot, Clinical trial, Anxiety, Digital, SAMD, Fine chemical, Pharmaceutical industry, Medical device, Vicor Corporation

Today they announce positive results from the pilot phase of a clinical study[2]for one of their digital therapies treating anxiety in patients with the rare disease IPF.

Key Points: 
  • Today they announce positive results from the pilot phase of a clinical study[2]for one of their digital therapies treating anxiety in patients with the rare disease IPF.
  • The Pilot study was a 4-week, single-arm, decentralized, open-label clinical investigation in 10 patients with self-reported anxiety related to idiopathic pulmonary fibrosis (IPF).
  • "We're very pleased with these early efficacy results for one of our anxiety Digital Therapeutics'.
  • Alex Therapeutics is a digital therapeutics (DTx) company that partners with pharmaceutical companies to create and license digital therapies.

Gate Neurosciences Publishes Data Highlighting Novel Mechanism of Lead Rapid-Acting Oral Antidepressant and Provides Business Update

Retrieved on: 
Thursday, September 29, 2022
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Clinical Trials, Molecule, Safety, Hospital, Institutional review board, Patient, Pharmacology, Investigational New Drug, IGF2R, Research, Northwestern University, Rockefeller University, Physical, NMDA, Division, Annual general meeting, Sleep, The International Journal of Neuropsychopharmacology, Northwestern, Hippocampus, Depression, MADRS, FDA, Literature, Lists of diseases, IND, GABA, Mental health, CEO, Board of directors, Method, Board, Eli Lilly, Electroencephalography, Plasma, Half-life, Precision medicine, Canadian International Council, Psychiatry, Biomarker, Publication, Massachusetts General Hospital, Therapy, Interneuron, Ataxia, Prefrontal cortex, Authorization, CNS, EEG, AbbVie, NMDAR, Depressive, Pharmaceutical industry, Apimostinel, MDD, Rapastinel

Publication highlights robust preclinical profile and novel mechanism for lead Phase 2 clinical program, Zelquistinel

Key Points: 
  • Publication highlights robust preclinical profile and novel mechanism for lead Phase 2 clinical program, Zelquistinel
    The peer-reviewed manuscript spotlights Zelquistinels novel mechanism and pharmacology by which it elicits rapid and long-lasting antidepressant effects.
  • These data highlight Zelquistinels novel, potent, and highly differentiated mechanism of action with potential for a significantly improved safety profile compared to other NMDAR-targeted antidepressants in development for depressive disorders.
  • Published in several peer-reviewed journals highlighting novel NMDAR mechanism and antidepressant activity of lead programs.
  • Gate Neurosciences lead programs are highly differentiated from other NMDAR-targeted antidepressants by acting through positive modulation instead of antagonism.

Adolescents Face Risk of Depressive Symptoms Immediately Following a Concussion

Retrieved on: 
Wednesday, August 31, 2022
National, Program, Research, News, Volunteering, Grammatical mood, U.S. News & World Report, Depression, Population, Prussia, Twitter, University of Pennsylvania School of Nursing, Facebook, Adult, Stroke, Risk, Depressive, Health, Patient, Fellow, Concussion, RN, PROMIS, CIRP, Department, Hospital, Center, FAAN, Pennsylvania Department of Aging, Comparison, U.S. News & World Report Best Hospitals Rankings, Cyclothymia, Children's Hospital of Philadelphia, LinkedIn, School, Mental health, U.S. News & World Report Best Colleges Ranking, BSN, Community health, University, CHOP, National Institute, Doctor of Philosophy, Associate, Education, Philadelphia, Lists of diseases, Minds, Spinal cord injury research, Sports Health, Pharmaceutical industry, Medicine, Science, Nursing, Anxiety

PHILADELPHIA, Aug. 31, 2022 /PRNewswire/ -- Researchers from Children's Hospital of Philadelphia (CHOP) and the University of Pennsylvania School of Nursing (Penn Nursing) have shown that adolescents reported elevated depressive symptoms in the period immediately following a concussion. The findings, which were recently published online in the journal Sports Health, underscore the need for more comprehensive screening when caring for adolescents who suffer a concussion.

Key Points: 
  • PHILADELPHIA, Aug. 31, 2022 /PRNewswire/ --Researchers from Children's Hospital of Philadelphia (CHOP) and the University of Pennsylvania School of Nursing (Penn Nursing) have shown that adolescents reported elevated depressive symptoms in the period immediately following a concussion.
  • Researchers from CHOP and Penn Nursing conducted a prospective study to assess mental health symptoms within the first 28 days after the injury and compare their results with non-concussed adolescents.
  • In initial analyses, the proportion of concussed adolescents above normal limits for depressive symptoms was greater than in the non-concussed groups.
  • In addition, more than 30% of the concussed adolescents were above normal limits for depressive or anxiety symptoms.

Limitless Guided Visualizations App Provides A Major Breakthrough in Mental Health Support Options

Retrieved on: 
Wednesday, August 17, 2022
Meditation, Depression, Psychotherapy, Metacognition, Google Play, Mental health, GLOBE, Psychopathology, Consciousness, Trauma, Limitless, Depressive, Rest, SAN, Lists of diseases, App Store (iOS/iPadOS), Magnetic resonance, Anxiety, Awareness, Yoga, Mental disorder, CAS, Distress, App store, Solution, Health, Medicine

SAN JOSE, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Limitless Guided Visualizations (Limitless), a mental health and wellness app, announced today its cognitive support product as an up-and-coming contribution to treating the mental health epidemic.

Key Points: 
  • SAN JOSE, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Limitless Guided Visualizations (Limitless), a mental health and wellness app, announced today its cognitive support product as an up-and-coming contribution to treating the mental health epidemic.
  • The Limitless app helps people reflect on their thought processes and reframe the relationship they have with themselves, thus improving their metacognition.
  • Limitless Guided Visualizations is a mental health and wellness app that empowers people to become the champion of their own personal health journeys.
  • The Limitless Guided Visualizationsapp is free to download in the App Store and on Google Play .

Recovery Centers of America Appoints Distinguished Mental Health Experts for New Behavioral Health Strategy and Treatment Services

Retrieved on: 
Tuesday, July 5, 2022
Diagnosis, Aetna, Hospital of the University of Pennsylvania, Patient, Anxiety, Bipolar, SUD, United States Public Health Service, Mental health service, COVID, Dialectical behavior therapy, Depressive, Element, U.S. News & World Report, Personality, Addiction, Fortune (magazine), Trauma, University, Friends Hospital, Sleep, MAT, News, Fear, Lists of diseases, RCA, DRS, Counselor, Mirror Lake Recovery Center, UN, Mental health, Program, Appetite, Hospital, Medical device, Medicine, Health insurance, Balance, Medicine

KING OF PRUSSIA, Pa., July 5, 2022 /PRNewswire/ -- The mental health crisis in America is showing no signs of slowing and Recovery Centers of America (RCA) is greatly expanding services to address the need for treatment by appointing two esteemed experts in the mental health treatment field to its leadership team

Key Points: 
  • This includes RCA's expansion into outpatient mental health services specially designed to treat patients who have mental health conditions as a primary diagnosis.
  • Dr. Vernig will oversee the expansion of mental health care across the organization including outpatient, inpatient, and digital health.
  • Dr. Vernig is well known in the mental health field and speaks widely on treatment for mental illness, emerging health trends , and modern behavioral health strategies.
  • Recovery Centers of America is dedicated to helping patients achieve a life of recovery through evidence-based alcohol and drug addiction treatment and mental health care.

First Blood Test to Diagnose Bipolar Disorder

Retrieved on: 
Thursday, June 9, 2022
Biomarker, Outpatient clinic (hospital department), Translational Psychiatry, Research, Mental health, Cyclothymia, Bipolar disorder, RNA editing, Artificial intelligence, Depression, Depressive, University, RNA, Professor, Partnership, Psychiatry, Innovation, Blood, Gene, IVDR, Conditional sentence, European Institute, Patient, Lists of diseases, Gene expression, Nature (journal), Wilfrid Sellars, UD, Diagnosis, Center, Department, BD, Technology, Medical device, Pharmaceutical industry, Synlab Group, Nature

MONTPELLIER, France and PARIS, June 9, 2022 /PRNewswire/ -- Alcediag, a French company specializing in precision psychiatry and a pioneer in biological diagnosis in mental health, announces the publication, in Nature: Translational Psychiatry, of a study that identified a panel of six blood biomarkers, major hallmarks of bipolar disorder.

Key Points: 
  • These results, recently published in the leading scientific journal Nature, have led to the development of the first diagnostic blood test for this disorder that affects more than 60 million people worldwide.
  • While the number of people suffering from depression is estimated at 300 million worldwide, up to 40% of them could actually be affected by bipolar disorder.
  • Yet, the management and treatments for bipolar disorder and depression differ significantly, making timely and reliable diagnosis paramount.
  • For the first time, the study led by Alcediag, including a cohort of 410 subjects, provides such a reliable, accurate test capable of differentiating the depressive phases of bipolar disorder from unipolar depression.

Compass Virtual Opens New Adult Evening Partial Hospitalization Program to Address Vast Disparities in Mental Health Treatment Options Across Illinois

Retrieved on: 
Tuesday, June 7, 2022
Program, Anxiety, Mental health, Partial, OCD, Teaching hospital, Fear, Suicide, Intensive outpatient program, Depressive, IOP, Patient, Bipolar, GLOBE, Anxiety disorder, LCSW, United States Public Health Service, PHP, Hospital, Medicine, Compass, Trauma, Depression

Programs only available during daytime working hours do not fit the needs of many people throughout Illinois.

Key Points: 
  • Programs only available during daytime working hours do not fit the needs of many people throughout Illinois.
  • "Compass Virtual's Evening Partial Hospitalization Program is designed to provide flexibility to those unable to join morning programs.
  • On June 6, Compass Virtual will expand care options by launching an Evening Partial Hospitalization Program (PHP) each weekday for individuals residing in Illinois, ages 18 and older.
  • Compass Health Center and Compass Virtual lead the way in providing patients with access to successful mental health services.